BackSHL Telemedicine Overview

SHL Telemedicine Other Current Liabilities

Track SHL Telemedicine's other current liabilities ($18M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$18.01M
108.50% YoYΔ $9.37M vs prior year quarter

Peer average

Loading

SHL Telemedicine Other Current Liabilities History

Loading

SHL Telemedicine vs. peers: Other Current Liabilities Comparison

Loading

SHL Telemedicine Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

SHL Telemedicine (SHLT) FAQ

SHL Telemedicine's other current liabilities stands at $18M as of December 2024. That compares with $8.6M in the prior-year period — up 108.5% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

SHL Telemedicine reported $18M in other current liabilities versus $8.6M a year earlier — a 108.5% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $8.6M in the prior-year period — up 108.5% year over year. Sustained growth in other current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how SHL Telemedicine's other current liabilities evolved across reporting periods, while the comparison chart places SHLT next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current liabilities is commonly used to spot outliers. SHL Telemedicine's reading of $18M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.